Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00023504
Other study ID # 010226
Secondary ID 01-I-0226
Status Terminated
Phase Phase 4
First received
Last updated
Start date June 13, 2002
Est. completion date October 14, 2021

Study information

Verified date October 2021
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate immune function in people with a known or suspected immune disorder. It will determine participants immune response to vaccines by measuring blood antibody levels after vaccination. Patients enrolled in a NIH protocol involving immune reconstitution (bone marrow transplantation or gene therapy) for a known or suspected primary immune disorder may be eligible for this study. Participants may be asked to have more than one vaccine, based on their age, use of IVIG, past immunization history and underlying immune problem. The possible vaccinations include: Rabies vaccine Diphtheria and tetanus booster 23 valent pneumococcal polysaccharide vaccine Pneumococcal 7-valent conjugate vaccine The diphtheria, tetanus, pneumococcus and rabies vaccines are approved by the Food and Drug Administration (FDA) and used routinely to protect against disease. Study participants will have a blood sample drawn before vaccination. The number of additional samples collected will vary according to the vaccines administered; 1 for rabies; 1 for tetanus; and 1 to 2 for the pneumococcal vaccines. Each sample will be up to 5 teaspoonfuls. Participation in the study may last up to a year, depending on the blood sampling scheduling


Description:

The purpose of this study is to evaluate immune responses to vaccines in subjects (both children and adults) with known or suspected primary immune disorders. We intend to characterize immune responsiveness to standard, well characterized antigens (vaccines) in subjects with primary immune disorders, and/or in subjects who have received treatments to correct their primary immune disorders. This will be an open label, prospective study investigating the functional status of the adaptive immune system. Up to 50 subjects may be enrolled. It is anticipated that subjects will be referred by any investigators at NIH studying inherited disorders of the immune system under their own protocols. After giving standard vaccines, we will test specific antibody. The vaccines include licensed and universally mandated diphtheria and tetanus toxoid, two licensed pneumococcal vaccine formulations recommended for protection of children from pneumonia, and rabies vaccine licensed in 1997 (not the formerly available reaction-prone formulation). We will obtain peripheral blood samples from subjects before vaccination and at a specific time intervals after vaccination. Measurement of specific antibody titers will be conducted by the immunology laboratory at the Department of Laboratory Medicin at the NIH. Subjects may be offered one or more of the vaccines based on available information about their exposure history and their immune status, and the vaccines may be offered sequentially or in combination to shorten study time. While the vaccines used here are often medically indicated and given outside of research protocols both to provide protection and to assess immune responses, the investigators have elected to use a protocol for the following reasons: - Enhancement of subject understanding of the use of vaccines for in vivo assessment of immune responses. - Emphasis on the importance of obtaining pre- and post-immunization blood samples to monitor how well the body's immune system is working. - Administration of rabies vaccine to subjects who would not ordinarily need it. - Recognition that vaccine side effects have been widely publicized and may be of concern to potential enrollees.


Recruitment information / eligibility

Status Terminated
Enrollment 21
Est. completion date October 14, 2021
Est. primary completion date May 22, 2017
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility - INCLUSION CRITERIA: Individuals being evaluated by NIH investigators for known or suspected primary immune disorders. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for at least 21 days prior to receipt of each vaccine and for the duration of study participation. EXCLUSION CRITERIA: Documented HIV infection. Active malignancy. Immunosuppressive therapy, other than steroids. Symptomatic cardiac disease or ongoing treatment for it. Pregnant or lactating women (due to restrictions on use of vaccines). Surgery during the two weeks prior to entry. Serious, ongoing, or uncontrolled infections. Platelet count less than 40,000/microL or other coagulation disorder. Any other major illness that, in the investigator's judgment, may substantially increase the risk associated with the patient's participation in this study. History of previous systemic reaction to the particular vaccine product being considered for administration. For RabAvert, persons known to be sensitive to: - Processed bovine gelatin - Chicken protein - Neomycin - Chlortetrycyline - Amphotericin B For Prevnar, persons with know or possible latex sensitivity. The effects of the vaccines on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for at least 21 days prior to each vaccine and for the duration of study participation. Females of child bearing age will have a pregnancy test prior to each vaccination. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform study staff and her primary care physician immediately.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Pneumovax
To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Rabavert
To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Prevnar
To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Tetanus diphtheria toxoid
To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.

Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post vaccine antibody level To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders. 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT05321407 - COVID-19 Vaccine Responses in PIDD Subjects
Completed NCT01199705 - Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) Phase 3
Recruiting NCT05070455 - An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) Phase 4
Recruiting NCT03836690 - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase 1
Completed NCT01461018 - Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study) Phase 3
Completed NCT04581460 - Primitive Immunodeficiency and Pregnancy
Recruiting NCT05476653 - A Prospective Monocentric Study to Assess the Concordance of Lung MRI Compared to Chest CT Scan to Assess the Extent and Severity of Bronchial and Parenchymal Pulmonary Lesions in Adult Patients With Primary Immune Deficiency (PID) . N/A
Completed NCT00419341 - Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy Phase 3
Active, not recruiting NCT02868333 - Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During Childhood N/A
Completed NCT01166074 - Retrospective Chart Review of Subcutaneous IgG Use in Infants N/A
Recruiting NCT05932316 - Evaluating Bronchodilator Response in Patients With Bronchiectasis N/A
Recruiting NCT04784364 - Biologics And Clinical Immunology Cohort at Sinai
Completed NCT06014463 - Evaluation of Adult Patients With Immunodeficiency Within the Scope of the ICF
Recruiting NCT04459689 - COVID-19 in PID Survey
Completed NCT02711228 - Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Phase 4
Recruiting NCT04919018 - Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies
Completed NCT00719680 - Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) Phase 3
Recruiting NCT00246857 - Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Recruiting NCT04565015 - Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency Phase 3
Recruiting NCT04702243 - Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults